Full-length inhibitor protein is the most effective to perturb human dUTPase activity
Abstract It has been demonstrated recently that knockout of the dUTPase enzyme leads to early embryonic lethality in mice. However, to explore the physiological processes arising upon the lack of dUTPase an effective and selective enzyme inhibitor is much needed. A highly specific and strong binding...
Saved in:
Main Authors: | Bianka Kőhegyi, Zoé S. Tóth, Enikő Gál, Máté Laczkovich, András Benedek, Beáta G. Vértessy, Kinga Nyíri |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-02-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86131-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01) -
Τhiazolidine-4-One Derivatives with Variable Modes of Inhibitory Action Against DPP4, a Drug Target with Multiple Activities and Established Role in Diabetes Mellitus Type II
by: Dionysia Amanatidou, et al.
Published: (2025-01-01) -
Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
by: Tobias Max Philipp Hartwich, et al.
Published: (2024-09-01) -
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
by: Xiaoyang Hong, et al.
Published: (2025-02-01) -
Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
by: Chalette Lambert-Swainston, et al.
Published: (2025-01-01)